All In Biotech

Drug Trial Radar · NCT05536011

WAKIX® (Pitolisant) Pregnancy Registry

WAKIX® (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,329

Planned (sponsor's estimate)

Start

Aug 24, 2021

Primary completion

Jun 30, 2030

Study completion Jun 30, 2030

Sponsor

Sponsor type
Industry
First posted
Sep 10, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The WAKIX (pitolisant) Pregnancy Registry is a US-based, prospective, observational cohort study designed to evaluate the association between pitolisant exposure during pregnancy and subsequent maternal, fetal, and infant outcomes.

Conditions

  • Pregnancy Related
  • Narcolepsy

Interventions

  • PitolisantDrug

    Exposure to at least one dose of pitolisant at any time during pregnancy

  • Comparator ProductsDrug

    Exposure to at least one dose of a comparator product at any time during pregnancy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major congenital malformationTime frame: Enrollment through the infant's first year of life

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Evidera (PPD)

    Morrisville, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.